TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $4.93 billion. The enterprise value is $4.94 billion.
Important Dates
The last earnings date was Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 145.90 million shares outstanding. The number of shares has increased by 11.64% in one year.
| Current Share Class | 145.90M |
| Shares Outstanding | 145.90M |
| Shares Change (YoY) | +11.64% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | 7.32% |
| Owned by Institutions (%) | 72.51% |
| Float | 135.16M |
Valuation Ratios
The trailing PE ratio is 12.18 and the forward PE ratio is 23.33. TG Therapeutics's PEG ratio is 0.15.
| PE Ratio | 12.18 |
| Forward PE | 23.33 |
| PS Ratio | 9.28 |
| Forward PS | 6.06 |
| PB Ratio | 17.77 |
| P/TBV Ratio | 17.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.15 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 11.03 |
| EV / Sales | 9.28 |
| EV / EBITDA | 48.00 |
| EV / EBIT | 48.02 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 2.48 |
| Debt / FCF | n/a |
| Interest Coverage | 3.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.15% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $1.57M |
| Profits Per Employee | $1.32M |
| Employee Count | 338 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -359.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.69% in the last 52 weeks. The beta is 2.01, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | +25.69% |
| 50-Day Moving Average | 33.64 |
| 200-Day Moving Average | 34.92 |
| Relative Strength Index (RSI) | 47.01 |
| Average Volume (20 Days) | 1,881,960 |
Short Selling Information
The latest short interest is 23.81 million, so 16.32% of the outstanding shares have been sold short.
| Short Interest | 23.81M |
| Short Previous Month | 23.61M |
| Short % of Shares Out | 16.32% |
| Short % of Float | 17.62% |
| Short Ratio (days to cover) | 13.15 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $531.90 million and earned $447.47 million in profits. Earnings per share was $2.78.
| Revenue | 531.90M |
| Gross Profit | 453.93M |
| Operating Income | 102.78M |
| Pretax Income | 87.75M |
| Net Income | 447.47M |
| EBITDA | 102.83M |
| EBIT | 102.78M |
| Earnings Per Share (EPS) | $2.78 |
Full Income StatementBalance Sheet
The company has $251.87 million in cash and $254.53 million in debt, giving a net cash position of -$2.66 million or -$0.02 per share.
| Cash & Cash Equivalents | 251.87M |
| Total Debt | 254.53M |
| Net Cash | -2.66M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 276.43M |
| Book Value Per Share | 1.90 |
| Working Capital | n/a |
Full Balance SheetMargins
Gross margin is 85.34%, with operating and profit margins of 19.32% and 84.13%.
| Gross Margin | 85.34% |
| Operating Margin | 19.32% |
| Pretax Margin | 16.50% |
| Profit Margin | 84.13% |
| EBITDA Margin | 19.33% |
| EBIT Margin | 19.32% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.64% |
| Shareholder Yield | -11.64% |
| Earnings Yield | 9.07% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for TG Therapeutics is $48.20, which is 42.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.20 |
| Price Target Difference | 42.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 38.57% |
| EPS Growth Forecast (5Y) | 97.69% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
